We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Quanterix recently entered into a collaboration with Sony DADC for the development and manufacture of "smart consumables" based on an optical disc format. This method was published online in Lab on a Chip.

"We have developed a device that enables the fluidic sealing and isolation of single molecules in arrays containing hundreds of thousands of miniaturized wells. These consumables are manufactured using high precision and high volume manufacturing processes, and will be at the heart of the SiMoA instrument that we are currently developing. By using arrays enclosed in microfluidic channels we are able to perform SiMoA in a fully automated fashion." said David Duffy, Ph.D., Vice President of Research at Quanterix and corresponding author of the publication. "This represents a significant milestone towards our goal of developing an automated platform that enables single molecule sensitivity while offering significant advantages for the manufacture of high quality, low–cost consumables. These devices will facilitate high throughput and sensitive detection of biomarkers, and address important applications in life science research and in vitro diagnostics."

Martin Madaus, Ph.D., Quanterix Chairman and CEO added, "This achievement is an important step towards our goal to commercialize the SiMoA technology. Working closely with our strategic partners, Quanterix plans to develop and manufacture a fully automated instrument for its SiMoA technology that will utilize these consumables to support a menu of diagnostic tests. Quanterix expects to launch the life science instrument in 2013, followed by an IVD platform to be commercialized in 2014."